Back to news

Radnostix, Inc. Reports FY2026 3rd Quarter and Nine Months Results - Theranostics Sales Up 15% Year-over-Year, Signs Agreement to Sell Fluorine Products/DUF6 Assets to Nano Nuclear Energy, Submits Type II DMF for Sodium Iodide I-131 API

PR Newswire•16/11/2026•12:05 ET
1

Key Highlights

  • ➤DUF6 asset sale to Nano Nuclear Energy totals $13.5 million, subject to NRC approval
  • ➤Q3 revenue $2.57 million, down 22% year-over-year, amid Cobalt delays and cobalt-57 shortages
  • ➤Q3 Theranostics revenue $1.71 million, up 15% year-over-year, with segment income rising
  • ➤Nine-month net loss $3.07 million versus $0.48 million, while cash fell to $0.71 million
  • ➤Approximately $1.2 million of delayed Cobalt contracts moved to Q1 2027

Expert Statements

Shahe Bagerdjian, President and Chief Executive Officer of Radnostix

“The third quarter showed the recovery of our core Theranostics business, with volumes restored in July and revenue up 15% over last year, and we took an important step to support a customer's NDA with our Type II DMF submission for Sodium Iodide I-131 API.”

Shahe Bagerdjian, President and Chief Executive Officer of Radnostix

“Our Cobalt and Calibration & Reference results were held back by contract timing tied to NRC sealed source amendments and by a global cobalt-57 supply interruption, but we have since begun shipping Gd-153 products for the first time since the global outage.”

Shahe Bagerdjian, President and Chief Executive Officer of Radnostix

“The agreement to sell our Fluorine Products/DUF6 assets to Nano Nuclear Energy, which remains subject to NRC approval and other closing conditions, would allow us to focus on our core radioisotope and medical device businesses.”

Shahe Bagerdjian, President and Chief Executive Officer of Radnostix

“We are still focused on developing our medical devices and building stronger OEM relationships with camera companies for our Calibration & Reference products.”

Shahe Bagerdjian, President and Chief Executive Officer of Radnostix

“Our priorities for the fourth quarter and into 2027 are clear: grow core revenues, convert our Cobalt and Calibration & Reference Products backlog, finalize launch of our Medical Devices products, and control costs.”

Radnostix, Inc. Reports FY2026 3rd Quarter and Nine Months Results - Theranostics Sales Up 15% Year-over-Year, Signs Agreement to Sell Fluorine Products/DUF6 Assets to Nano Nuclear Energy, Submits Type II DMF for Sodium Iodide I-131 API PR Newswire

IDAHO FALLS, Idaho, Nov. 16, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its financial results for the third quarter and nine months ended September 30, 2026 and the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in